IL-11 receptor inhibition tied to osteosarcoma
In a paper published in Proceedings of the National Academy of Sciences, researchers showed that targeting the alpha subunit of the IL-11 receptor (IL-11R) with the bone metastasis-targeting peptidomimetic BMTP-11 reduces metastases and tumor growth. The team suggested that targeting the receptor could be used to treat high-risk osteosarcoma.
Spokesperson Vincent Anzalone told BioCentury that Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) has rights to BMTP-11, but does not currently plan to develop it further. The company obtained its rights in 2012 via its acquisition of Alvos Therapeutics Inc. (see BioCentury, Dec. 24, 2012)...
BCIQ Target Profiles